Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Vaccine ; 40(45): 6489-6498, 2022 10 26.
Artículo en Inglés | MEDLINE | ID: mdl-36195474

RESUMEN

The rapid spread of COVID-19 on all continents and the mortality induced by SARS-CoV-2 virus, the cause of the pandemic coronavirus disease 2019 (COVID-19) has motivated an unprecedented effort for vaccine development. Inactivated viruses as well as vaccines focused on the partial or total sequence of the Spike protein using different novel platforms such us RNA, DNA, proteins, and non-replicating viral vectors have been developed. The high global need for vaccines, now and in the future, and the emergence of new variants of concern still requires development of accessible vaccines that can be adapted according to the most prevalent variants in the respective regions. Here, we describe the immunogenic properties of a group of theoretically predicted RBD peptides to be used as the first step towards the development of an effective, safe and low-cost epitope-focused vaccine. One of the tested peptides named P5, proved to be safe and immunogenic. Subcutaneous administration of the peptide, formulated with alumina, induced high levels of specific IgG antibodies in mice and hamsters, as well as an increase of IFN-γ expression by CD8+ T cells in C57 and BALB/c mice upon in vitro stimulation with P5. Neutralizing titers of anti-P5 antibodies, however, were disappointingly low, a deficiency that we will attempt to resolve by the inclusion of additional immunogenic epitopes to P5. The safety and immunogenicity data reported in this study support the use of this peptide as a starting point for the design of an epitope restricted vaccine.


Asunto(s)
COVID-19 , Vacunas Virales , Cricetinae , Humanos , Ratones , Animales , SARS-CoV-2 , Epítopos , Glicoproteína de la Espiga del Coronavirus/genética , Vacunas contra la COVID-19 , COVID-19/prevención & control , Anticuerpos Antivirales , Inmunoglobulina G , Péptidos , ARN , Óxido de Aluminio , Anticuerpos Neutralizantes
2.
World J Gastroenterol ; 12(27): 4318-24, 2006 Jul 21.
Artículo en Inglés | MEDLINE | ID: mdl-16865772

RESUMEN

AIM: To study the effect of mucilage obtained from cladodes of Opuntia ficus-indica (Cactaceae) on the healing of ethanol-induced gastritis in rats. METHODS: Chronic gastric mucosa injury was treated with mucilage (5 mg/kg per day) after it was induced by ethanol. Lipid composition, activity of 5'-nucleotidase (a membrane-associated ectoenzyme) and cytosolic activities of lactate and alcohol dehydrogenases in the plasma membrane of gastric mucosa were determined. Histological studies of gastric samples from the experimental groups were included. RESULTS: Ethanol elicited the histological profile of gastritis characterized by loss of the surface epithelium and infiltration of polymorphonuclear leukocytes. Phosphatidylcholine (PC) decreased and cholesterol content increased in plasma membranes of the gastric mucosa. In addition, cytosolic activity increased while the activity of alcohol dehydrogenases decreased. The administration of mucilage promptly corrected these enzymatic changes. In fact, mucilage readily accelerated restoration of the ethanol-induced histological alterations and the disturbances in plasma membranes of gastric mucosa, showing a univocal anti-inflammatory effect. The activity of 5'-nucleotidase correlated with the changes in lipid composition and the fluidity of gastric mucosal plasma membranes. CONCLUSION: The beneficial action of mucilage seems correlated with stabilization of plasma membranes of damaged gastric mucosa. Molecular interactions between mucilage monosaccharides and membrane phospholipids, mainly PC and phosphatidylethanolamine (PE), may be the relevant features responsible for changing activities of membrane-attached proteins during the healing process after chronic gastric mucosal damage.


Asunto(s)
Adhesivos/análisis , Adhesivos/uso terapéutico , Mucosa Gástrica/patología , Gastritis/tratamiento farmacológico , Opuntia/química , 5'-Nucleotidasa/análisis , Adhesivos/administración & dosificación , Adhesivos/farmacología , Administración Oral , Animales , Colesterol/análisis , Enfermedad Crónica , Citosol/enzimología , Etanol , Mucosa Gástrica/efectos de los fármacos , Gastritis/inducido químicamente , Gastritis/patología , Masculino , Fluidez de la Membrana/efectos de los fármacos , Lípidos de la Membrana/química , Neutrófilos/patología , Fosfolípidos/análisis , Extractos Vegetales/administración & dosificación , Extractos Vegetales/análisis , Extractos Vegetales/farmacología , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA